---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-270019"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:24:05.560434+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS

## Summary
- Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.
- FY2025 revenue guidance narrowed to $36M-$38M; combined 2026 with IRRAS expected $54M-$60M.
- Signed agreement to acquire IRRAS Holdings; no purchase price disclosed.
- New CAL preclinical facility operational; FDA 510(k) clearance for 1.5T PRISM Laser Therapy.
- Active biopharma partners >60; plan to activate 35-40 specialized centers for cell/gene therapy.

## SEC filing metadata
- accession: 0001193125-25-270019
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000119312525270019/0001193125-25-270019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000119312525270019/clpt-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-270019
- JSON: https://secwatch.observer/filing/0001193125-25-270019.json
- Plain text: https://secwatch.observer/filing/0001193125-25-270019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.